PTGS2 and adenoma: In a randomized, double-blind, placebo-controlled trial involving 1,561 subjects who had previously undergone adenoma removal, daily treatment with the COX-2 inhibitor celecoxib at a dose of 400 mg decreased detection through year three by 35.7% [10].